More importantly, clinical research data have not observed that DPP1 inhibitor treatment significantly increases serious infection risks, supporting the conclusion that DPP1 inhibition has relatively limited impact on host defense functions within therapeutic dose ranges (Zhong et al., 2025; Chalmers et al., 2025b; Tadayasu et al., 2025). The gene discussed is CTSC; the disease is infection.